Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Y-mAbs Therapeutics, Inc. (YMAB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/09/2023 |
4
| Hamill Laura (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 2,330 shares
@ $0
Granted 13,950 options to buy
@ $8.13, valued at
$113.4k
|
|
| 06/09/2023 |
4
| Wedell-Wedellsborg Johan (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 2,330 shares
@ $0
Granted 13,950 options to buy
@ $8.13, valued at
$113.4k
|
|
| 06/09/2023 |
4
| Ber Gerard (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 2,330 shares
@ $0
Granted 13,950 options to buy
@ $8.13, valued at
$113.4k
|
|
| 06/09/2023 |
4
| GILL DAVID N (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 2,330 shares
@ $0
Granted 13,950 options to buy
@ $8.13, valued at
$113.4k
|
|
| 06/09/2023 |
4
| HEALY JAMES (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 2,330 shares
@ $0
Granted 13,950 options to buy
@ $8.13, valued at
$113.4k
|
|
| 06/09/2023 |
4
| TYAGI ASHU (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 2,330 shares
@ $0
Granted 13,950 options to buy
@ $8.13, valued at
$113.4k
|
|
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/26/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/17/2023 |
4
| Wedell-Wedellsborg Johan (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Bought 101,740 shares
@ $9.6462, valued at
$981.4k
|
|
| 05/17/2023 |
4
| WG Biotech ApS (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Bought 101,740 shares
@ $9.6462, valued at
$981.4k
|
|
| 05/08/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/03/2023 |
SC 13G
| ACORN BIOVENTURES, L.P. reports a 5.3% stake in Y-mAbs Therapeutics, Inc. |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 02/14/2023 |
SC 13G/A
| HBM Healthcare Investments Ltd. reports a 8.7% stake in Y-mAbs Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| WG Biotech ApS reports a 9.8% stake in Y-mAbs Therapeutics, Inc. |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.2% stake in Y-mAbs Therapeutics Inc. |
| 02/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/30/2023 |
4
| Lisby Steen (SVP & CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 32,000 options to buy
@ $4.55, valued at
$145.6k
|
|
| 01/30/2023 |
4
| Lund-Hansen Torben (SVP & CHIEF TECHNICAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 32,000 options to buy
@ $4.55, valued at
$145.6k
|
|
| 01/30/2023 |
4
| Rajah Vignesh (SVP & CHIEF MEDICAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 32,000 options to buy
@ $4.55, valued at
$145.6k
|
|
| 01/30/2023 |
4
| Smith Susan Laura (SVP & CHIEF COMMERCIAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 32,000 options to buy
@ $4.55, valued at
$145.6k
|
|
| 01/30/2023 |
4
| Wilms Joris (SVP & COO) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 32,000 options to buy
@ $4.55, valued at
$145.6k
|
|
| 01/19/2023 |
4
| Rajah Vignesh (SVP & CHIEF MEDICAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.|
Txns:
| Granted 17,800 shares
@ $0
Granted 35,700 options to buy
@ $4.7, valued at
$167.8k
|
|
|
|
|